Clinical trial
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
NCT05761171 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
- Lead sponsor
- Children's Oncology Group
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- January 8, 2024
- Completion date
- December 31, 2027
- Enrollment
- 78 (estimated)
- Sites
- 84
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent acute leukemia of ambiguous lineage, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia due to lineage switch from acute leukemia of ambiguous lineage, recurrent acute myeloid leukemia due to lineage switch from b acute lymphoblastic leukemia, kmt2a-rearranged, recurrent acute myeloid leukemia due to lineage switch from mixed phenotype acute leukemia, recurrent mixed phenotype acute leukemia, refractory acute leukemia of ambiguous lineage, refractory acute lymphoblastic leukemia, refractory acute myeloid leukemia due to lineage switch from acute leukemia of ambiguous lineage, refractory acute myeloid leukemia due to lineage switch from b acute lymphoblastic leukemia, kmt2a-rearranged, refractory acute myeloid leukemia due to lineage switch from mixed phenotype acute leukemia, refractory mixed phenotype acute leukemia